Comparing theraputic response to systemic Meglumine Antimoniate (Glucantime) in children with acute Cutaneous Leishmaniasis versus adult patients

Evaluation of theraputic response to systemic Meglumine antimoniate (Glucantime) in children with acute Cutaneous Leishmaniasis comparing with adult patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804162082N1

Enrollment

Registered

2009-09-14

Start date

2006-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis. Cutaneous leishmaniasis

Interventions

Intramuscular (I.M.) glucantime with dosage of 60mg/kg/day for 20 days.

Treatment - Drugs

Intramuscular (I.M.) glucantime with dosage of 60mg/kg/day for 20 days

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with acute cutaneous leishmaniasis (more than 4 months duration) Exclusion criteria: 1. History of allergy to Glucantim 2. History of Cardiac, Renal or hepatic diseases 3. Pregnancy or breast feeding 4. Performing other treatment for Cutaneous leishmaniasis during the study or in the last 3-month 5. If the patient was not available for follow-up of the treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Complete healing. Timepoint: at the end of 20th day of treatment and 45 days after finishing the treatment schedule. Method of measurement: Measurment of induration of the lesions ( ulcers).	—

Secondary

Measure	Time frame
Adverse Effects. Timepoint: Recorded at each follow-up visit. Method of measurement: Taking medical history and performing physical examination.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026